Abstract
A National Institutes of Health proposal will restrict the licensing of Federally funded biomedical research tools for commercial gain.
References
Marshall, E. Science 278, 212–213 (1997); Adler, R.G. The New Biologist 2, 495–497 (1990).
35 USC §§ 200 et seq.
Intellectual Property Rights and Research Tools in Molecular Biology. Summary of a study held at the National Academy of Sciences, Feb. 15–16, 1996.
Report of the NIH Working Group on Research Tools, p. 4, June 4, 1998.
See Eisenberg, R. 5 Risk: Health Safety & Environment 163 (1994). Professor Eisenberg has also argued in favor of a research exemption from the patent laws. See Eisenberg, R. 56 U. Chi. L. Rev. 1017 (1989).
See NIH Proposed Guidelines for Recipients of NIH Research Grants and Contracts on Obtaining and Disseminating Biomedical Research Resources; Request for Comments, 64 Fed. Reg., No. 100, May 25, 1999, pp. 28205–28209.
Id. at 28206.
Id.
Id. at 28205, fn.1.
Id.
Id. at 28207.
Id.
Id. at 28206.
Id.
National Academy Study, Chapter 5, Case Studies, "Protein and DNA sequencing instruments: Research tools to which strong patent protection promoted broad access.".
Id.
Id.
Undocumented conversation with Dr. Leroy Hood .
35 USC § 203.
35 USC § 203(1)(a) through (d).
35 USC § 202(a)(ii).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Flores, M. Taking the profit out of biomedical research tools. Nat Biotechnol 17, 819–820 (1999). https://doi.org/10.1038/11774
Issue Date:
DOI: https://doi.org/10.1038/11774
- Springer Nature America, Inc.
This article is cited by
-
Patents on genes: clarifying the issues
Nature Biotechnology (2000)